logo-loader
viewCytoDyn Inc.

CytoDyn continues to works on licensing deals as FDA continues its review on patient data

CytoDyn (OTCQB: CYDY) President and Chief Executive Officer Nader Pourhassan joined Steve Darling from Proactive to discuss a number of issues including the very latest on their clinical trials for a COVID-19 treatment. Pourhassan also told Proactive that they are in discussions with numerous groups about licensing deals for the drugs.

Quick facts: CytoDyn Inc.

Price: 6.08 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $3.16 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn continues to report strong results from COVID-19...

CytoDyn Inc (OTCQB: CYDY) President and CEO Nader Pourhassan and Bruce Patterson, M.D. and Chief Executive Officer and founder of IncellDx joined Steve Darling from Proactive Vancouver with news the company continues to see more impressive results from COVID-19 patients who have received...

on 30/4/20

2 min read